Philosophy of Care
Dr. Gholami believes in an innovative, individualized, multi-disciplinary treatment approach to provide the most compassionate, highest quality of cancer care for her patients and their families.
Dr. Gholami is a board-certified surgeon scientist with dual fellowship training in Complex General Surgical Oncology and Hepatopancreatobiliary Surgery. She believes in precision-medicine using evidence-based best practice to develop a personalized treatment plan for each patient.
Dr. Gholami specializes in surgeries of the gastrointestinal tract, liver, biliary tree, and the pancreas. Her clinical interests include innovative approaches to cancer care including minimally invasive surgery and robotic techniques as well as liver-directed therapies/regional therapies in patients with hepatobiliary and metastatic malignancies.
Dr. Gholami's research focus includes translational science and clinical trials to advance the understanding of hepatobiliary and pancreas tumor genetics, microenvironment, and immune profiling. She believes in innovative, personalized medical treatment through stratifying tumors on their genetic and immunologic features to achieve the best oncologic outcomes and highest quality of care.
Dr. Gholami has extensive research experience in vaccine and targeted therapies which have resulted in multiple publications and clinical trials. She is currently involved in developing clinical trials with novel therapeutics related to immune-activating agents as well as targeted therapies in combination with liver-directed/regional therapies in patients with hepatobiliary malignancies. In addition, Dr. Gholami is interested in clinical outcomes research to improve medical care related to cancer surgery at the National level.
M.D., Stanford University School of Medicine, Palo Alto CA 2008
B.S., UC Davis, Davis CA 2003
Internship: General Surgery, Stanford University Hospital, Palo Alto CA 2009
General Surgery, Stanford University Hospital, Palo Alto CA 2010-2012
Research-Scientist Complex and General Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York NY 2010-2012
Hepatopancreatobiliary Surgery, Memorial Sloan Kettering Cancer Center, New York NY 2016-2017
American Board of Surgery - General Surgery, 2016
daVinci Surgical Platform, 2017
American Association of Cancer Research
American College of Surgeons
American Hepato-Pancreato-Biliary Association
American Society of Clinical Oncology
Association for Academic Surgeons
Association of Women Surgeons
Society of Surgical Oncology
Honors and Awards
Hilary Sanfey Outstanding Resident Award (Association of Women Surgeons), 2014
Stanford General Surgery Resident Research Award, 2013
Recipient of the Nina Starr American Women Surgeon Research Award, 2012
Stanford General Surgery Resident Research Award, 2012
Highly-rated paper awardat (American Association of Cancer Research), 2012
Select Recent Publications
Gholami S, Cassidy MR, Strong VE. Minimally Invasive Surgical Approaches to Gastric Resection. Surg Clin North Am. 2017 Apr;97(2):249-264. Review.
Cassidy MR, Gholami S, Strong VE. Minimally Invasive Surgery: The Emerging Role in Gastric Cancer. Surg Oncol Clin N Am. 2017 Apr;26(2):193-212. Review.
Strong VE, Gholami S, Shah MA, Tang LH, Janjigian YY, Schattner M, Selby LV, Yoon SS, Salo-Mullen E, Stadler ZK, Kelsen D, Brennan MF, Coit DG. Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients. Ann Surg. 2016 Oct 17.
Gholami S, Janson L, Worhunsky DJ, Tran TB, Squires MH 3rd, Jin LX, Spolverato G, Votanopoulos KI, Schmidt C, Weber SM, Bloomston M, Cho CS, Levine EA, Fields RC, Pawlik TM, Maithel SK, Efron B, Norton JA, Poultsides GA.Number of Lymph Nodes Removed and Survival after Gastric Cancer Resection: An Analysis from the US Gastric Cancer Collaborative. J Am Coll Surg. 2015 Aug;221(2):291-9.
Eveno C, Mojica K, Ady JW, Thorek DL, Longo V, Belin LJ, Gholami S, Johnsen C, Zanzonico P, Chen N, Yu T, Szalay AA, Fong Y. Gene therapy using therapeutic and diagnostic recombinant oncolytic vaccinia virus GLV-1h153 for management of colorectal peritoneal carcinomatosis. Surgery. 2015 Feb;157(2):331-7.
Gholami S, Marano A, Chen NG, Aguilar RJ, Frentzen A, Chen CH, Lou E, Fujisawa S, Eveno C, Belin L, Zanzonico P, Szalay A, Fong Y.A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer. Breast Cancer Res Treat. 2014 Dec;148(3):489-99.
Gholami S, Chen CH, Lou E, Belin LJ, Fujisawa S, Longo VA, Chen NG, Gönen M, Zanzonico PB, Szalay AA, Fong Y.Vaccinia virus GLV-1h153 in combination with 131I shows increased efficiency in treating triple-negative breast cancer. FASEB J. 2014 Feb;28(2):676-82.
Gholami S, Chen CH, Belin LJ, Lou E, Fujisawa S, Antonacci C, Carew A, Chen NG, De Brot M, Zanzonico PB, Szalay AA, Fong Y.Vaccinia virus GLV-1h153 is a novel agent for detection and effective local control of positive surgical margins for breast cancer. Breast Cancer Res. 2013 Mar 18;15(2):R26.
Au JT, Kingham TP, Jun K, Haddad D, Gholami S, Mojica K, Monette S, Ezell P, Fong Y. Irreversible electroporation ablation of the liver can be detected with ultrasound B-mode and elastography. Surgery. 2013 Jun;153(6):787-93.
Gholami S, Chen CH, Lou E, De Brot M, Fujisawa S, Chen NG, Szalay AA, Fong Y. Vaccinia virus GLV-1h153 is effective in treating and preventing metastatic triple-negative breast cancer. Ann Surg. 2012 Sep;256(3):437-45.